

## TABLE OF CONTENTS

|                                                                                |   |
|--------------------------------------------------------------------------------|---|
| INTRODUCTION .....                                                             | 1 |
| WORLDWIDE MARKETING APPROVAL STATUS .....                                      | 1 |
| ACTIONS TAKEN IN THE REPORTING PERIOD FOR SAFETY REASONS .....                 | 1 |
| CHANGES TO REFERENCE SAFETY INFORMATION .....                                  | 1 |
| INVENTORY OF CLINICAL TRIALS ONGOING AND COMPLETED DURING THE REPORTING PERIOD | 1 |
| ESTIMATED CUMULATIVE EXPOSURE .....                                            | 1 |
| Cumulative Subject Exposure in Development Programme .....                     | 1 |
| Patient Exposure from Marketing Experience .....                               | 1 |
| DATA IN LINE LISTINGS AND SUMMARY TABULATIONS .....                            | 2 |
| Reference Information .....                                                    | 2 |
| Line Listings of Serious Adverse Reactions during the Reporting Period.....    | 2 |
| Cumulative Summary Tabulations of Serious Adverse Events .....                 | 2 |
| SIGNIFICANT FINDINGS FROM CLINICAL TRIALS DURING THE REPORTING PERIOD .....    | 2 |
| Completed Clinical Trials .....                                                | 2 |
| Ongoing Clinical Trials .....                                                  | 2 |
| Long-term Follow up .....                                                      | 2 |
| Other Therapeutic Use of Investigational Drug.....                             | 2 |
| New Safety Data Related to Combination Therapies .....                         | 2 |
| SAFETY FINDINGS FROM NON-INVESTIGATIONAL STUDIES .....                         | 2 |
| OTHER CLINICAL TRIAL/STUDY SAFETY INFORMATION .....                            | 2 |
| SAFETY FINDINGS FROM MARKETING EXPERIENCE .....                                | 2 |
| NON-CLINICAL DATA .....                                                        | 3 |
| LITERATURE .....                                                               | 3 |
| OTHER DSURs .....                                                              | 3 |
| LACK OF EFFICACY .....                                                         | 3 |
| REGION-SPECIFIC INFORMATION .....                                              | 3 |
| Cumulative summary tabulation of Serious Adverse Reactions .....               | 3 |

---

|                                                                                      |   |
|--------------------------------------------------------------------------------------|---|
| List of subjects who died during the reporting period .....                          | 3 |
| List of subjects who dropped out of clinical trial during the reporting period ..... | 3 |
| LATE-BREAKING INFORMATION .....                                                      | 3 |
| OVERALL SAFETY ASSESSMENT .....                                                      | 4 |
| Evaluation of the Risks .....                                                        | 4 |
| Benefit-risk Considerations .....                                                    | 4 |
| SUMMARY OF IMPORTANT RISKS .....                                                     | 4 |
| CONCLUSIONS .....                                                                    | 4 |
| APPENDICES TO THE DSUR .....                                                         | 4 |